NCT06878872

Brief Summary

Before the 1990s, obesity was rare among young people with type 1 diabetes (T1D), but now it is more common. Recent studies show that over 50% of young people with T1D will have overweight or obesity within five years of being diagnosed with T1D. Both obesity and T1D increase the risk of heart disease, and combined, these risks are even higher. Intensive health behavior and lifestyle treatments (IHBLTs) are proven to be effective for treating childhood obesity. However, managing T1D creates unique challenges that require adjustments to these treatments. For example, people with T1D need to eat even when they're not hungry to treat low blood sugar, blood sugar changes can make exercise harder, and some recommended "free foods" are high in unhealthy fats. Young people with T1D are also more likely to develop eating disorders. There is a need for IHBLTs that address these specific challenges and focus on preventing eating disorders in this group. To address these needs, we developed the Type 1 Diabetes Adolescents for healthier Lifestyles (T1DAL) program, based on feedback from teenagers with T1D, their parents/caregivers, and pediatric endocrinologists. The goal of this study is to test whether the T1DAL program can improve the health and wellbeing of teens compared to usual care. In this study, about 50 teens will be randomly assigned to either the T1DAL program or to Usual Care. Those in the T1DAL group will take part in a 16-week program designed specifically for teens with T1D to improve eating habits and diabetes management. Those in the Usual Care group will continue with their regular endocrinology appointments. At the end of the study, the Usual Care group will be offered a shortened version of the T1DAL program. All participants will have their height, weight, blood glucose, eating habits, diabetes management behaviors, and mood measured at the start and end of the study. They will also answer questions to track unhealthy eating and weight control behaviors over time. Additional analyses will look at factors that may lead to these behaviors in real life. This project builds on Dr. Warnick's previous work in pediatric obesity and T1D, and it supports the NIDDK's goal of reducing diabetes-related heart problems. T1DAL could become an important public health program to improve the health of teens with T1D.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
14mo left

Started May 2025

Typical duration for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress47%
May 2025Jun 2027

First Submitted

Initial submission to the registry

March 5, 2025

Completed
12 days until next milestone

First Posted

Study publicly available on registry

March 17, 2025

Completed
2 months until next milestone

Study Start

First participant enrolled

May 1, 2025

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2027

Last Updated

April 3, 2025

Status Verified

March 1, 2025

Enrollment Period

2.2 years

First QC Date

March 5, 2025

Last Update Submit

April 2, 2025

Conditions

Keywords

TeenagersDiabetesType 1 Diabetes

Outcome Measures

Primary Outcomes (2)

  • BMI Change

    Change in body mass index

    baseline, 4-months

  • Time in Range Change

    Change in time in the recommended glucose range (70-180 mg/dL)

    baseline, 4-months

Secondary Outcomes (1)

  • Events of Unhealthy Weight Control Behaviors

    baseline, 4-months

Other Outcomes (1)

  • Correlates of Unhealthy Weight Control Behaviors

    baseline, 4-months

Study Arms (2)

T1DAL Program

EXPERIMENTAL

Adolescent intensive health behavior and lifestyle treatment adapted for a type 1 diabetes population

Behavioral: T1DAL Program

Usual Care

NO INTERVENTION

Adolescents continue their typical diabetes treatment management.

Interventions

T1DAL ProgramBEHAVIORAL

T1DAL is a 16-week behavioral program. Teens meet in virtual groups and individually with a health coach throughout the program. Teens learn healthy lifestyle behaviors specific to living with type 1 diabetes and get opportunities to connect with other teens who are living with type 1 diabetes.

T1DAL Program

Eligibility Criteria

Age13 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Teen diagnosed with type 1 diabetes at least 6 months ago
  • Teen's body mass index greater than or equal to the 70th percentile for age and sex
  • Teen lives with parent/caregiver
  • Teen has access to a smart phone
  • Teen and caregiver speak and write in fluent English

You may not qualify if:

  • Teen has a medical condition that precludes them from participating in a group activity and/or any physical activity
  • Teen experiencing psychosis or suicidality
  • Teen lost a significant amount of weight in the 3 months prior to the study
  • Teen currently in another intensive health behavior and lifestyle treatment and/or sees a dietician more than once per month on average
  • Teen currently or planning to become pregnant
  • Teen unwilling to wear a continuous glucose monitor for assessments
  • Teen taking a medication known to impact weight and/or appetite

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Diabetes Mellitus, Type 1Feeding BehaviorPediatric ObesityDiabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System DiseasesBehavior, AnimalBehaviorObesityOverweightOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Jenny Warnick, PhD

    The Miriam Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jenny Warnick, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 5, 2025

First Posted

March 17, 2025

Study Start

May 1, 2025

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

June 30, 2027

Last Updated

April 3, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Please contact the PI for a request of de-identified data.